A Critical Systematic Review of Budget Impact Analyses on Drugs in the EU Countries
Author
Abstract
Suggested Citation
DOI: 10.1007/s40258-013-0064-7
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Valentin Brodszky & Petra Baji & Orsolya Balogh & Márta Péntek, 2014. "Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 65-71, May.
- Joost W. Geenen & Svetlana V. Belitser & Rick A. Vreman & Martijn Bloois & Olaf H. Klungel & Cornelis Boersma & Anke M. Hövels, 2020. "A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(6), pages 845-853, August.
- Josephine Mauskopf & Stephanie Earnshaw, 2016. "A Methodological Review of US Budget-Impact Models for New Drugs," PharmacoEconomics, Springer, vol. 34(11), pages 1111-1131, November.
- Joost W. Geenen & Cornelis Boersma & Olaf H. Klungel & Anke M. Hövels, 2019. "Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 857-867, August.
- Nathalie Vernaz & François Girardin & Nicolas Goossens & Urs Brügger & Marco Riguzzi & Arnaud Perrier & Francesco Negro, 2016. "Drug Pricing Evolution in Hepatitis C," PLOS ONE, Public Library of Science, vol. 11(6), pages 1-12, June.
- Natalie Carvalho & Mark Jit & Sarah Cox & Joanne Yoong & Raymond C. W. Hutubessy, 2018. "Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Frame," PharmacoEconomics, Springer, vol. 36(1), pages 79-90, January.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:12:y:2014:i:1:p:33-40. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.